期刊文献+

α-甲酰基辅酶A消旋酶在前列腺腺癌诊断和鉴别诊断中的作用 被引量:35

Assessment of P504S immunohistochemistry in diagnosis and differential diagnosis of prostatic adenocarcinoma
原文传递
导出
摘要 目的 观察α 甲酰基辅酶A消旋酶 (α methylacyl CoAracemase ,P5 0 4S)在前列腺腺癌的诊断和鉴别诊断中的价值。方法 对前列腺腺癌及其需要鉴别的病变 :前列腺上皮内瘤变、不典型腺瘤样增生、不典型小腺泡增生以及正常前列腺组织 (包括萎缩的腺体 )和良性增生进行光镜观察 ,用EnVision二步法免疫组织化学方法检测P5 0 4S、细胞角蛋白 (CK) 34βE12、p6 3在各类病变组织中的表达情况。根据P5 0 4S阳性表达部位区分其表达形式为 :胞质型、腔缘型、顶端胞质型及胞膜型。结果  78例前列腺腺癌中 ,91% (71/ 78)阳性表达P5 0 4S ,多表现为癌细胞弥漫性胞质内阳性着色较深的颗粒状物 ,少数为腺腔内缘或顶端胞质内及膜表达 ,9% (7/ 78)阴性表达P5 0 4S者均为亮细胞型 ;前列腺上皮内瘤变 (9例 ) ,不典型腺瘤样增生 (6例 )以及不典型小腺泡增生 (2例 )中均见P5 0 4S不同程度的表达 ;96 % (6 5 / 6 8)的正常及良性增生前列腺组织未见P5 0 4S阳性表达 ;增生的基底细胞也未见P5 0 4S阳性表达。结论 P5 0 4S的免疫组织化学染色对判断前列腺腺癌具有重要参考价值 ,若与CK34βE12或 p6 Objective To assess the utility of P504S immunohistochemistry in the diagnosis and differential diagnosis of prostatic adenocarcinoma.Methods Light microscopy and immunohistochemistry examinations (EnVision^(TM) staining) were performed in 117 cases of prostatic adenocarcinoma, PIN, AAH, ASAP, BPH and normal prostatic tissue to correlate the morphology and protein expression of P504S, 34βE12, and P63. Results Seventy-one of the 78 (91%) cases of prostatic adenocarcinoma stained positive for P504S, with strong cytoplasmic granular staining in most cases, and a weak or intense granular staining along the circumferential luminal and apical cell border membrane in a few cases. Negative P504S immunostaining was observed in 7 of 78 (9%) cases of prostatic adenocarcinoma, all of which were clear cell type prostatic adenocarcinoma. Cases of PIN (9 cases), AAH (6 cases) and ASAP (2 cases) showed various expression levels of P504S. Sixty-five of 68 (96%) cases of normal prostates and BPH were negative for P504S and basal cell hyperplasia cases were also negative. Conclusions P504S is a useful marker for microscopic diagnosis of prostatic adenocarcinoma, and immunohistochemistry study using a combination of P504S and 34βE12/p63 may be of greater benefit in aiding the differential diagnoses.
出处 《中华病理学杂志》 CAS CSCD 北大核心 2004年第5期419-423,共5页 Chinese Journal of Pathology
关键词 前列腺腺癌 阳性表达 不典型 辅酶A 良性增生 前列腺上皮内瘤 前列腺组织 目的观 状物 结论 Prostatic neoplasms Immunohistochemistry Racemases and epimerases Diagnosis, differential
  • 相关文献

参考文献10

  • 1Xu J, Stolk JA, Zhang X, et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarry. Cancer Res, 2000,60: 1677-1682.
  • 2Jiang Z, Woda BA, Rock KL, et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol, 2001, 25: 1397-1404.
  • 3Beach R, Gown AM, De Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol, 2002,26:1588-1596.
  • 4Magi-Galluzzi C, Luo J, Isaacs WB, et al. Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. Am J Surg Pathol, 2003,27:1128-1133.
  • 5Mostofi FK, Sesterhenn IA, Davis CJ, et al. Histological typing of prostate tumours. WHO, Geneva. Heidelberg: Springer, 2002.
  • 6Chen L, Jiang Z, Woda BA, et al. Decreased expression of alpha-methylacyl-CoA racemase/P504S in foamy gland carcinoma of the prostate. Mod Pathol, 2003, 16: 145A.
  • 7Zhou M, Jiang Z, Epstein JI. Expression and diagnostic utility of alpha-methylacyl-CoA racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer. Am J Surg Pathol, 2003, 27:772-778.
  • 8Gupta N, De Peralta-Venturina MN, Gown A, et al. P504S antibody expression in putative precursor lesions of prostate carcinoma(PCa)-high grade prostatic intraepithelial neoplasia(HGPIN) and atypical adenomatous hyperplasia(AAH). Mod Pathol, 2003, 16:152A.
  • 9Yang XJ, Wu CL, Woda BA, et al. Expression of alpha-methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol, 2002, 26:921-925.
  • 10姜众,马珂,吴群力,杨熙明.诊断前列腺癌的一种新的标记物——α-甲酰基辅酶A消旋酶[J].中华病理学杂志,2004,33(5):401-403. 被引量:11

二级参考文献27

  • 1Epstein J, Yang X. Prostate Biopsy Interpretation. Philadelphia: Lippincott Williams & Wilkins, 2002.
  • 2Young R, Sringley J, Amin M. Tumors of the prostate glands, seminal vesicles, male urethra, and penis. Washington, D.C.: Armed Forces Institute of Pathology, 2000.
  • 3Wang MC, Valenzuela LA, Murphy GP, et al. A simplified purification procedure for human prostate antigen. Oncology, 1982, 39:1-5.
  • 4Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol,1999,162:293-306.
  • 5Beckett ML, Lipford GB, Haley CL, et al. Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas. Cancer Res, 1991, 51:1326-1333.
  • 6Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature, 2001, 412:822-826.
  • 7Gown AM, Vogel AM. Monoclonal antibodies to human intermediate filament proteins. II. Distribution of filament proteins in normal human tissues. Am J Pathol, 1984, 114:309-321.
  • 8Signoretti S, Waltregny D, Dilks J, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol, 2000, 157:1769-1775.
  • 9Wojno KJ, Epstein JI. The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases. Am J Surg Pathol, 1995,19:251-260.
  • 10Xu J, Stolk JA, Zhang X, et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res, 2000, 60:1677-1682.

共引文献10

同被引文献308

引证文献35

二级引证文献77

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部